Reducing Stigma Through a Mental Health Art Exhibition and Its Printed Brochure

January 26, 2025 updated by: Wei Zhou, Hunan University

Reducing Stigma Through a Mental Health Art Exhibition and Its Printed Brochure: an Social-contact Intervention Study

Mental health art exhibitions, as an intervention strategy integrating artistic expression and social contact, have the potential to positively impact the elimination of stigma and discrimination associated with mental health problems. Based on a two-phase experimental design, this study aims to evaluate the effect of a real-world mental health art exhibition (Phase One) and its printed brochure (Phase Two) on stigma/discrimination and related outcomes, such as mental health literacy. The evaluation will encompass three categories of people: those with lived experience of mental disorders, family members and friends of those with lived experience, and the general public. Qualitative methods, such as in-depth interviews, will also be used for the evaluation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Mental health art exhibitions, as an intervention strategy integrating artistic expression and social contact, have the potential to positively impact the elimination of stigma and discrimination associated with mental health problems. Based on a two-phase experimental design, this study aims to evaluate the effect of a real-world mental health art exhibition (Phase One) and its printed brochure (Phase Two) on stigma/discrimination and related outcomes, such as mental health literacy. The evaluation will encompass three categories of people: those with lived experience of mental disorders, family members and friends of those with lived experience, and the general public. Qualitative methods, such as in-depth interviews, will also be used for the evaluation.

The intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 14, 2024. Organized by "Qixi Charity", an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health.

At Phase One, the effect of the real-world exhibition is evaluated through a single-arm pre-post study design. The adult audience, who are individuals with lived experience of mental disorders, or family members and friends of those with lived experience, or the general public, will be recruited as the experimental group, and they will be surveyed three times: (1) a baseline survey before the interventions (T0); (2) a follow-up survey in the first month after the interventions (T1); (3) a follow-up survey in the sixth month after the interventions (T2). Additionally, the study will perform text analysis of media reports and social media discussions related to the exhibition to supplement the assessment of its social impact.

Due to the high costs and limited feasibility of widespread implementation of the real-world Mental Health Art Exhibition, the intervention was then adapted to a printed exhibition brochure. At Phase Two, the effect of the brochure intervention in reducing stigma and other related outcomes will be assessed and compared with a traditional health education brochure and a postcard as a placebo. Individuals with lived experience of mental disorders, or family members and friends of those with lived experience, or the general public, who do not visit the exhibition of Phase One, will be recurited. After that, individuals with lived experience of mental disorders and their family members or friends will be cluster-randomized to either the exhibition brochure group or the control group (the latter typically receives or seeks out traditional health education materials during healthcare visits). As for the general public will be cluster-randomized into three groups: (1) the exhibition brochure group, (2) the traditional health education brochure group, and (3) the control group. Effectiveness will be evaluated through three surveys: (1) a baseline survey before the interventions (T0); (2) a follow-up survey one month after the interventions (T1); and (3) a follow-up survey six months after the interventions (T2).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
360

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
    • Hubei
      • Wuhan, Hubei, China, 430000
        • Recruiting
        • Qixi Charity
        • Contact:
    • Hunan
      • Changsha, Hunan, China, 410000
        • Recruiting
        • The Second Xiangya Hospital, Central South University
        • Contact:
      • Changsha, Hunan, China, 410087
        • Recruiting
        • Hunan University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

General Inclusion Criteria:

  • Adults aged 18 and above

General Exclusion Criteria:

  • Individuals who are unable to understand the content of the questionnaire due to illness and other factors
  • Mental health professionals, including psychiatrists, psychologists, nurses, social workers and medical students

Additional Inclusion Criteria for Phase One:

  • Individuals who attend the exhibition offline

Additional Inclusion Criteria for Phase Two:

  • Individuals who did not visit the exhibition of Phase One

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: an exhibition group
At Phase One, participants of this group are those who attend the offline art exhibition. At Phase Two, participants of this group are those who cannot attend the offline exhibition and will be provied with a printed brochure of the exhibition.
Other: A mental health art exhibition
The specific intervention measure is the Second Mental Health Art Science Exhibition scheduled to take place in Wuhan, China from April 27 to May 27, 2024. Organized by "Qixi Charity", an NGO led by individuals with lived experience of mental disorders, as well as their family members and friends, the exhibition will feature offline artworks created by these individuals and other contributors. The exhibited artworks aim to reflect the diverse dimensions of mental health and ill-health.
Active Comparator: an education group
At Phase Two, participants in this group are those who are unable to attend the offline art exhibition but will be provided with printed/online education materials
Other: printed or online education materials
The specific intervention measure is to provide printed or online education materials within the first month after the baseline survey
No Intervention: Control Group
At Phase Two, participants in this group are those who cannot attend the exhibition offline and will be provided with a postcard.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Stigma/discrimination regarding mental disorders
Time Frame: Time point 0: before the exhibition; Time point 1: within the first month after the exhibition; Time point 2: the sixth month after the exhibition
Individuals with lived experience of mental disorders: internalized stigma of mental illness scale (ISMI-29), the perceived devaluation discrimination scale (PDD-12) Family members and friends of those with lived experience: affiliate stigma scale (ASS-22), the perceived devaluation discrimination scale (PDD-12) The general public: community attitudes toward mental ill scale (CAMI-20), attribution questionnaire (AQ-9), the perceived devaluation discrimination scale (PDD-12)
Time point 0: before the exhibition; Time point 1: within the first month after the exhibition; Time point 2: the sixth month after the exhibition

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
mental health literacy
Time Frame: Time point 0: before the exhibition; Time point 1: within the first month after the exhibition; Time point 2: the sixth month after the exhibition
All participants: mental health and care knowledge questionnaire (MHCK-16)
Time point 0: before the exhibition; Time point 1: within the first month after the exhibition; Time point 2: the sixth month after the exhibition

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Willingness to pay
Time Frame: T2: six months after the interventions (T2)
Individuals with lived experience of mental disorders & family members and friends of those with lived experience: maximum and minimum amount of money willing to pay for treating the suffering mental health conditions The general public: maximum and minimum amount of money willing to pay for treating 2 mental health conditions and 2 general health conditions in vignettes
T2: six months after the interventions (T2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Hunan University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Central South University
Qixi Charity

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Wei Zhou, Ph.D., Hunan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 12, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 30, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 12, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 15, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 26, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 531118232022

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Health Issue

Clinical Trials on A mental health art exhibition

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings